Entity

Time filter

Source Type

Kempten (Allgäu), Germany

Heigl F.,Medical Care Center Kempten Allgaeu | Hettich R.,Medical Care Center Kempten Allgaeu | Lotz N.,Medical Care Center Kempten Allgaeu | Reeg H.,Medical Care Center Kempten Allgaeu | And 4 more authors.
Atherosclerosis Supplements | Year: 2015

LDL cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) are main risk factors for cardiovascular disease (CVD).Efficacy, safety, and tolerability of lipoprotein apheresis (LA) were investigated in 36,745 LA treatments of 118 patients with CVD in a retrospective, monocentric study. Indications were severe hypercholesterolemia (n=83) or isolated Lp(a) hyperlipoproteinemia (n=35). Average age of patients at start of LA treatment was 58.1 years for males and 62.5 years for females. Medium interval between the first cardiovascular event and LA treatment was 6.4±5.6 years and the average LA treatment period was 6.8±4.9 years. On average treatments were performed once a week, via peripheral venous access in 79.3% of non-hemodialysis patients. In patients with hypercholesterolemia initial pre-LA LDL-C was lowered from 176.4±67.0mg/dL by 66.7±10.8% per session, achieving a long-term interval mean value of 119.8±34.7mg/dL, i.e. reduction by 32.1±19.6% (p<0.0001). In patients with isolated elevated Lp(a) initial pre-LA Lp(a) was lowered from 127.2±67.3mg/dL by 66.8±5.8% per session, achieving a long-term interval mean value of 60.0±19.5mg/dL, i.e. reduction by 52.8±23.0% (p<0.0001). After start of LA the average annual rate of major adverse coronary events (MACE) of all patients declined by 79.7% (p<0.0001). Subgroup analysis showed decline by 73.7% (p<0.0001) in patients with severe hypercholesterolemia, and by 90.4% (p<0.0001) in patients with isolated elevated Lp(a). Adverse events (AE) occurred in 1.1% of treatments. LA treatment of patients with high risk for CVD due to LDL and/or Lp(a) hyperlipoproteinemia was effective, safe, and well tolerated. The number of cardiovascular events, at least during a six-year period, declined by 80%. © 2015 Elsevier Ireland Ltd. Source


Heigl F.,Medical Care Center Kempten Allgaeu | Hettich R.,Medical Care Center Kempten Allgaeu | Lotz N.,Medical Care Center Kempten Allgaeu | Reeg H.,Medical Care Center Kempten Allgaeu | And 4 more authors.
Clinical Research in Cardiology Supplements | Year: 2015

Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) are established causal risk factors for cardiovascular disease (CVD). Efficacy, safety, and tolerability of lipoprotein apheresis (LA) were investigated in 118 patients with CVD covering a period with 36,745 LA treatments in a retrospective, monocentric study. Indications for LA were severe hypercholesterolemia (n = 83) or isolated Lp(a) hyperlipoproteinemia (Lp(a)-HLP) (n = 35). In patients with hypercholesterolemia, initial pre-LA LDL-C was 176.4 ± 67.0 mg/dL. In patients with isolated Lp(a)-HLP, initial pre-LA Lp(a) was 127.2 ± 67.3 mg/dL. Mean reduction rates of LA were 67 % for both LDL-C and Lp(a). During chronic LA, the average annual rate of major adverse cardiac events of all patients declined by 79.7 % (p < 0.0001). Subgroup analysis showed decline by 73.7 % (p < 0.0001) in patients with severe hypercholesterolemia, and by 90.4 % (p < 0.0001) in patients with isolated Lp(a)-HLP. Adverse events occurred in 1.1 % of treatments. LA treatment of patients with a high risk for CVD due to hypercholesterolemia and/or Lp(a)-HLP demonstrated clinical benefit and was safe and well tolerated. © 2015, The Author(s). Source

Discover hidden collaborations